Elucidating the Risks and Benefits of Withholding Biologics to Optimize Surgical Outcomes
Bibliographic record
Abstract
Editorials18 June 2019Elucidating the Risks and Benefits of Withholding Biologics to Optimize Surgical OutcomesCorrection(s) for this article:CorrectionsOct 2019Correction: Withholding Biologics to Optimize Surgical OutcomesFREEBheeshma Ravi, MD, PhD and Gillian Hawker, MD, MScBheeshma Ravi, MD, PhDUniversity of Toronto, Toronto, Ontario, Canada (B.R., G.H.)Search for more papers by this author and Gillian Hawker, MD, MScUniversity of Toronto, Toronto, Ontario, Canada (B.R., G.H.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M19-1088 SectionsSupplemental MaterialAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail This article has been corrected. The original version (PDF) is appended to this article as a Supplement.The introduction of biologic therapies for the treatment of rheumatoid arthritis (RA) has resulted in a paradigm shift in the experience of RA for both patients and clinicians. These genetically engineered therapies target and disrupt specific immune system signals that cause and perpetuate the disease. Although not a cure for RA, biologic therapies can dramatically slow disease progression—but they may also increase risk for infection.George and colleagues (1) report a retrospective cohort study that used administrative claims data (Medicare and Truven MarketScan) ...References1. George MD, Baker JF, Winthrop K, Alemao E, Chen L, Connolly S, et al. Risk of biologics and glucocorticoids in patients with rheumatoid arthritis undergoing arthroplasty. A cohort study. Ann Intern Med. 2019;170:825-36. doi:10.7326/M18-2217 LinkGoogle Scholar2. Goodman SM, Springer B, Guyatt G, Abdel MP, Dasa V, George M, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Rheumatol. 2017;69:1538-51. [PMID: 28620948] doi:10.1002/art.40149 CrossrefMedlineGoogle Scholar3. Strand V, Ahadieh S, French J, Geier J, Krishnaswami S, Menon S, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:362. [PMID: 26669566] doi:10.1186/s13075-015-0880-2 CrossrefMedlineGoogle Scholar4. Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386:258-65. [PMID: 25975452] doi:10.1016/S0140-6736(14)61704-9 CrossrefMedlineGoogle Scholar5. Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015:CD005468. [PMID: 25887212] doi:10.1002/14651858.CD005468.pub2 CrossrefMedlineGoogle Scholar6. Cordtz RL, Zobbe K, Højgaard P, Kristensen LE, Overgaard S, Odgaard A, et al. Predictors of revision, prosthetic joint infection and mortality following total hip or total knee arthroplasty in patients with rheumatoid arthritis: a nationwide cohort study using Danish healthcare registers. Ann Rheum Dis. 2018;77:281-8. [PMID: 29097373] doi:10.1136/annrheumdis-2017-212339 CrossrefMedlineGoogle Scholar7. Ravi B, Croxford R, Hollands S, Paterson JM, Bogoch E, Kreder H, et al. Increased risk of complications following total joint arthroplasty in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:254-63. [PMID: 24504797] doi:10.1002/art.38231 CrossrefMedlineGoogle Scholar8. Katz JN, Barrett J, Mahomed NN, Baron JA, Wright RJ, Losina E. Association between hospital and surgeon procedure volume and the outcomes of total knee replacement. J Bone Joint Surg Am. 2004;86-A:1909-16. [PMID: 15342752] CrossrefMedlineGoogle Scholar9. Ravi B, Croxford R, Austin PC, Hollands S, Paterson JM, Bogoch E, et al. Increased surgeon experience with rheumatoid arthritis reduces the risk of complications following total joint arthroplasty. Arthritis Rheumatol. 2014;66:488-96. [PMID: 24574207] doi:10.1002/art.38205 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of Toronto, Toronto, Ontario, Canada (B.R., G.H.)Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-1088.Corresponding Author: Gillian Hawker, MD, MSc, Department of Medicine, Suite RFE 3-805, 190 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada; e-mail, g.[email protected]ca.Current Author Addresses: Dr. Ravi: Department of Orthopaedic Surgery, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada.Dr. Hawker: Department of Medicine, Suite RFE 3-805, 190 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada.This article was published at Annals.org on 21 May 2019. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoRisk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty Michael D. George , Joshua F. Baker , Kevin Winthrop , Evo Alemao , Lang Chen , Sean Connolly , Jesse Y. Hsu , Teresa A. Simon , Qufei Wu , Fenglong Xie , Shuo Yang , and Jeffrey R. Curtis Correction: Withholding Biologics to Optimize Surgical Outcomes Metrics Cited byCorrection: Withholding Biologics to Optimize Surgical OutcomesInfections with bDMARDs and glucocorticoids before arthroplasty 18 June 2019Volume 170, Issue 12Page: 886-887KeywordsArthroplastyBiologicsCohort studiesGlucocorticoid therapyHipJoint replacement surgeryKneesMethotrexateProsthetic device infectionsSurgeons ePublished: 21 May 2019 Issue Published: 18 June 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.008 | 0.074 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.002 | 0.001 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.004 | 0.002 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.003 | 0.005 |
| Insufficient payload (model declined to judge) | 0.027 | 0.008 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".